Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biologics for Pediatric Psoriasis Don’t Increase Infection Risk

Key clinical point: Psoriasis itself increases the risk of serious infections in children and adolescents.

Major finding: In nonbiologic initiators, the 6-month risk of serious infections was 4.75 per 1,000 patients, while in biologic initiators it was 5.44 per 1,000 patients, resulting in a propensity score–matched ratio of 0.60.

Study details: A population-based study of 54,355 children with psoriasis.

Disclosures: The study was funded by the Brigham and Women’s Hospital departments of dermatology and medicine. Dr. Schneeweiss and Dr. Huang reported having no financial disclosures. Dr. Merola reported that he has served as a consultant and/or investigator for numerous pharmaceutical companies.